Mercks spending big to support Gardasil, and the HPV vaccine keeps pumping along
Merck & Co.ís immuno-oncology superstar Keytruda has been dominating headlines and sales rankings for the pharma giant, but it has another growth engine making waves around the world, too.
HPV vaccine Gardasil 9 has been pumping in recent years, and the trend continued in the second quarter. The shot posted 50% growth at constant exchange rates over last years second quarter to $886 million. And the company is gearing up to keep the shots growth coming.